Previous close | 597.00 |
Open | 598.38 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 595.10 - 603.90 |
52-week range | 336.03 - 673.62 |
Volume | |
Avg. volume | 1,604 |
Market cap | 44.686B |
Beta (5Y monthly) | 0.61 |
PE ratio (TTM) | 35.60 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 4.57 (0.76%) |
Ex-dividend date | 13 May 2024 |
1y target est | N/A |
BOSTON & BASEL, Switzerland, June 26, 2023--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Lonza (SIX: LONN) today announced a strategic collaboration to support the manufacture of Vertex’s portfolio of investigational stem cell-derived, fully differentiated insulin-producing islet cell therapies for people with T1D, currently focusing on the VX-880 and VX-264 programs that are currently in clinical trials.